This page shows what was measured, who it was measured in, and what that does not settle.
What Desmopressin does in the body
Passing far too much urine because the body is missing the hormone that concentrates it — and, separately, bleeding in mild haemophilia A or mild von Willebrand disease
Desmopressin is a rebuilt copy of the hormone your pituitary releases when you are dehydrated. Two small changes to the original hormone make it last much longer and stop it squeezing blood vessels, so all that is left is the water-saving signal. It lands on a receptor that sits on two different tissues: kidney tubes, which respond by pulling water back out of the urine, and the lining of blood vessels, which respond by emptying a stored packet of clotting protein into the blood.
What happened in people
0.65 fewer units of red cells and 254 mL less blood lost per patient across ten randomised cardiac surgery trials in 596 participants
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
That the factor VIII rise reduces bleeding in mild haemophilia A or type I von Willebrand disease — the licensed indications rest on the laboratory response, with no randomised bleeding-outcome trial behind them
Where it acts
Kidney collecting duct principal cells, and the Weibel-Palade bodies inside vascular endothelial cells
Kind of result
A number that stands in for health
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · ENR1LLB0FP · read 2026-08-29
Its recorded molecular formula is C46H64N14O12S2·C2H4O2, weighing 1129.30 g/mol.
US prescribing information · 4c0e1356-d14f-cfb4-e063-6294a90acd27 · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 137 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 19 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Sleep
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Pain
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
…Waiting for a reviewer1 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Sleep
wake after sleep onset; sleep efficiency; sleep
Pain
pain
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Perioperative allogeneic red cell transfusion and blood loss
✓ The study showed what it set out to show
Who was studied
Desborough meta-analysis of desmopressin for platelet dysfunction in cardiac surgery
How many people
596
Study design
Systematic review and meta-analysis of ten randomised controlled trials
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Red cells: mean difference -0.65 units (95% CI -1.16 to -0.13). Blood loss: -253.93 mL (95% CI -408.01 to -99.85). Re-operation for bleeding: Peto OR 0.39 (95% CI 0.18-0.84)
Repeated elsewhere
Partially Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. The authors state there were too few events to determine whether thrombotic risk changed, and grade the evidence very low to moderate certainty.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous or subcutaneous injection, oral tablet, sublingual tablet and nasal spray
Interval reported. 95% CI -1
Written into the record, not signed off as a reviewed claim.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
Percentage change from baseline in factor VIII coagulant activity and plasminogen activator
✓ The study showed what it set out to show
Who was studied
FDA-approved labelling basis for the haemophilia A and type I von Willebrand indications
How many people
0
Study design
Pharmacodynamic characterisation, no randomised bleeding-outcome trial
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Maximal 300 to 400 percent change from baseline; increase evident within 30 minutes, maximum at 90 minutes to two hours
Repeated elsewhere
Unreplicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. A sample size of zero is the accurate entry: there is no randomised controlled trial with a bleeding endpoint behind either haemostatic indication. The licensing evidence is a laboratory response.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous or subcutaneous injection, oral tablet, sublingual tablet and nasal spray
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
Number of people requiring allogeneic blood transfusion after hip fracture surgery
✗ The study did not show it
Who was studied
Cochrane overview of transfusion-reducing interventions in hip fracture surgery
How many people
3923
Study design
Overview of 26 systematic reviews covering 36 randomised trials
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
No result for desmopressin. The overview searched for it explicitly and found no systematic review of desmopressin in this population; only tranexamic acid and iron had any.
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. `endpoint met: false` here means the evidence does not exist, not that the drug failed a test.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Intravenous or subcutaneous injection, oral tablet, sublingual tablet and nasal spray
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
RNAWiki holds 3 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.2 registered measures of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.5 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat, Dog. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Start
Desmopressin
What a person takes: Intravenous or subcutaneous injection, oral tablet, sublingual tablet and nasal spray.
The measurement behind this step
The injection is used in hospital for bleeding and for acute management of diabetes insipidus. Tablets are the long-term route for diabetes insipidus. The nasal formulations delivered the drug efficiently and variably, and that variability is a large part of why they no longer exist in the United States.
Getting in
Injected, sprayed or swallowed — and very little of a tablet gets in
It is a small peptide, so the gut destroys most of it. The injection puts all of it into the blood at once; the tablet needs far more of it to achieve the same thing.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
A nine-residue cyclic peptide, not metabolised by CYP450, with a terminal half-life of 2.8 hours and 52% of an intravenous dose recovered unchanged in urine within 24 hours. Renal impairment extends the half-life to 8.7 hours in severe impairment and raises exposure 3.6-fold, which matters because the drug's hazard is cumulative water retention.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
It docks on the V2 receptor — on two entirely different tissues
The receptor it activates sits on kidney tubes and on the lining of blood vessels. The drug cannot tell them apart, which is why treating a bleed also switches on water retention.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Desmopressin is a selective agonist at the V2 vasopressin receptor. Deamination at position 1 and substitution of D-arginine at position 8 remove the V1-mediated vasopressor and visceral smooth muscle effects, so that antidiuretic concentrations sit below the threshold for vascular action. The V2 receptor is expressed on collecting duct principal cells and on vascular endothelium.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
Inside the kidney cell, water channels are moved to the surface
The receptor sets off a chemical messenger inside the cell, which causes ready-made water channels stored in little bubbles to be pushed into the cell wall. Water then flows back out of the urine.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
V2 activation couples through Gs to adenylate cyclase, raising cyclic AMP and activating protein kinase A, which phosphorylates aquaporin-2 and drives trafficking of aquaporin-2-bearing vesicles to the apical membrane of the collecting duct principal cell. Water then follows the medullary osmotic gradient out of the tubular lumen. Urine output falls, urine osmolality rises and plasma osmolality falls.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
Inside the blood vessel lining, a stored packet of clotting protein is emptied
The same signal in a different cell causes storage granules to fuse with the cell surface and release von Willebrand factor into the blood. That protein carries factor VIII and glues platelets to a wound.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
The same cyclic AMP rise triggers exocytosis of Weibel-Palade bodies from vascular endothelium, releasing stored von Willebrand factor multimers. Because von Willebrand factor is the circulating chaperone for factor VIII, factor VIII activity rises with it. This is release of a pre-formed store, not synthesis, which is why the response is exhausted by repeated dosing and absent where the store is absent.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
The urine concentrates, the clotting numbers rise, and the sodium falls
Both intended effects happen and both are easy to measure. So does the third one: holding on to water dilutes the blood, and if fluid keeps going in, the sodium level can drop far enough to cause seizures.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Factor VIII activity reaches 300 to 400 percent of baseline within 90 minutes to two hours. Urine output falls and urine osmolality rises. The label carries a boxed warning for hyponatraemia, which it describes as capable of causing seizures, coma, respiratory arrest or death, with contraindications in excessive fluid intake, loop diuretic or glucocorticoid use, and known or suspected SIADH.
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 5 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
changes in quality of life
pain
Measured
Things only a test, a scale or a device shows.
decrease in supine systolic blood pressure
cmax maximum observed concentration
24 hour urine volume
urine osmolality
urine volume
Meaningful
Things that change how a life goes, not only a number.
survival
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (11)
nocturnal voids
wake after sleep onset
sleep efficiency
sleep
blood loss
postoperative blood loss
adherence to intervention
treatment related adverse events as assessed by ctcae v4 0
duration of surgery
rate of recruitment
bleeding events
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 3.6 hours hours
Read from the label, which states: “Desmopressin estimated elimination half-life is 3.6 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
People with central diabetes insipidus, who take it indefinitely; people with mild haemophilia A or mild type I von Willebrand disease around surgery or after injury; and, until recently, adults with night-time urination and children who wet the bed.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Desmopressin acetate is indicated for the management of central diabetes insipidus as antidiuretic replacement therapy in pediatric patients.”
US prescribing information · 4c0e1356-d14f-cfb4-e063-6294a90acd27 · read 2026-08-30
On older people, the label states: “Because geriatric patients are more likely to have decreased renal function, care should be taken in dose selection and monitoring renal function is recommended [see Clinical Pharmacology (12.3)].”
US prescribing information · 4c0e1356-d14f-cfb4-e063-6294a90acd27 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Available data on the use of desmopressin acetate during pregnancy over decades of use have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
US prescribing information · 4c0e1356-d14f-cfb4-e063-6294a90acd27 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Breastfeeding is not expected to result in clinically relevant exposure of the infant to desmopressin following maternal administration.”
US prescribing information · 4c0e1356-d14f-cfb4-e063-6294a90acd27 · read 2026-08-30
On people with reduced kidney function, the label states: “Desmopressin acetate is substantially excreted by the kidney, and the risk of adverse events may be greater in patients with renal impairment than patients with normal renal function.”
US prescribing information · 4c0e1356-d14f-cfb4-e063-6294a90acd27 · read 2026-08-30
Where the result stopped carrying
The FDA required the nasal spray label to be revised in December 2007, after which it is no longer indicated for primary monosymptomatic nocturnal enuresis or in patients at risk of hyponatraemia
Stimate nasal spray was subject to a Class I recall on 21 July 2020 for superpotency and is now discontinued
Noctiva (approved 2017) and Nocdurna (approved 2018), both aimed at nocturia, are both discontinued, as is the original 1978 DDAVP nasal formulation
A 2023 Cochrane overview looking specifically for desmopressin evidence in hip fracture surgery found no systematic review of it at all
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Intravenous or subcutaneous injection, oral tablet, sublingual tablet and nasal spray
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S6.
No source is stored against this line.
What is in the pack
The injection is used in hospital for bleeding and for acute management of diabetes insipidus. Tablets are the long-term route for diabetes insipidus. The nasal formulations delivered the drug efficiently and variably, and that variability is a large part of why they no longer exist in the United States.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
A boxed warning for hyponatraemia, which the label describes as potentially life-threatening and capable of causing seizures, coma, respiratory arrest or death. Contraindicated with excessive fluid intake, in known or suspected SIADH, and with loop diuretics or systemic or inhaled glucocorticoids. May cause hypotension with reflex tachycardia, or hypertension. Use in type IIB von Willebrand disease may cause thrombosis through platelet aggregation. Fluid retention can destabilise heart failure and is not recommended where intracranial pressure may be raised. Exposure rises substantially with renal impairment.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
Where this came from
DDAVP (desmopressin acetate) injection — FDA-approved prescribing information, boxed warning and sections 1, 5 and 12, retrieved from the openFDA drug label … · a recorded source, not a stored snapshot
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Desmopressin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 556 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Intravenous or subcutaneous injection, oral tablet, sublingual tablet and nasal spray
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Tablets are the long-term route for diabetes insipidus. The nasal formulations delivered the drug efficiently and variably, and that variability is a large part of why they no longer exist in the United States.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on which forms are sold and how they compare.
No source is stored against this line.
What is recorded as being sold
91 products list this as an active ingredient in the United States drug directory. 91 of them contain it and nothing else.
FDA National Drug Code directory · 41701-007 · read 2026-08-29
They are sold as injection, injection, solution, powder, solution, spray and tablet, taken intravenous, nasal, oral and subcutaneous.
FDA National Drug Code directory · 41701-007 · read 2026-08-29
The regulator's established pharmacologic class for it is factor viii activator [epc], increased coagulation factor viii activity [pe] and increased coagulation factor viii concentration [pe].
FDA National Drug Code directory · 41701-007 · read 2026-08-29
43 published labels name it as an active ingredient. 43 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 7f4e5a22-85e8-4c28-9ebf-d6ebc75ad653 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 7f4e5a22-85e8-4c28-9ebf-d6ebc75ad653 · read 2026-08-29
DESMODA is oral at 3 DOSAGE FORMS AND STRENGTHS Oral solution: 0.05 mg desmopressin acetate in 1 mL (0.05 mg/mL) Oral solution: 0.05 mg desmopressin acetate in 1 mL (0.05 mg/mL) (3), recorded as fda label in effect 2026-03-02 in the United States.
US prescribing information · 4c0e1356-d14f-cfb4-e063-6294a90acd27 · read 2026-08-30
Recorded price in US: 0.23534–0.37006 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 15 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Recorded price in US: 9.28243–20.44088 USD per one millilitre, across 10 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Desmopressin studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That the factor VIII rise reduces bleeding in mild haemophilia A or type I von Willebrand disease — the licensed indications rest on the laboratory response, with no randomised bleeding-outcome trial behind them
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That an agent effective in mild disease will help in severe disease — the label excludes severe type I von Willebrand disease, and in type IIB it warns of thrombosis from platelet aggregation
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That hyponatraemia is a manageable inconvenience rather than the effect that removed four formulations from the market
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Desmopressin are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
Factor VIII activity rises 300 to 400 percent, and it rises within half an hour
In plain words
In people with mild haemophilia A or mild von Willebrand disease, an infusion pushes the missing clotting protein up three to four times over baseline, starting within thirty minutes and peaking around two hours.
What was measured
Percentage change from baseline in factor VIII coagulant activity, and time to peak
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The DDAVP injection label reports that the factor VIII and plasminogen activator response is dose-related, with maximal plasma levels of 300 to 400 percent change from baseline. The increase is evident within 30 minutes and reaches a maximum between 90 minutes and two hours. The duration of the haemostatic effect follows the half-life of factor VIII coagulant activity, about 8 to 12 hours. The percentage increase in patients with mild haemophilia A and von Willebrand disease was not significantly different from that seen in healthy individuals. The terminal half-life of the drug itself is 2.8 hours in normal renal function, rising to 4, 6.6 and 8.7 hours in mild, moderate and severe renal impairment, with area under the curve 1.5-, 2.4- and 3.6-fold higher respectively.
Written into the record, not signed off as a reviewed claim
The whole haemostatic indication rests on that laboratory rise, not on a bleeding trial
In plain words
The evidence that desmopressin helps bleeding in mild haemophilia and von Willebrand disease is that it raises a number in a test tube. No randomised trial has measured whether people bleed less.
What was measured
That a 300 to 400 percent rise in factor VIII translates into less bleeding — the step everyone takes and nobody has randomised
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The label's clinical basis for the haemophilia A and type I von Willebrand indications is the factor VIII response, and the indications are written around a laboratory threshold — factor VIII coagulant activity above 5% and no factor VIII antibodies. There is no randomised placebo-controlled trial with a bleeding outcome underpinning either indication. The nearest randomised evidence in any bleeding population is Desborough and colleagues' meta-analysis of ten trials and 596 participants, all in cardiac surgery and all in patients whose problem was platelet dysfunction rather than a factor deficiency; the GRADE quality of that evidence was graded very low to moderate, which the authors describe as considerable uncertainty. The mechanism is not in doubt. The clinical inference from the mechanism has not been tested in the licensed population.
Written into the record, not signed off as a reviewed claim
In cardiac surgery it removes about two thirds of a unit of blood per patient
In plain words
Pooled across ten randomised trials of heart surgery patients whose platelets were not working properly, desmopressin cut transfusion by roughly two thirds of a unit each, cut blood loss by about 250 mL, and more than halved the odds of going back to theatre for bleeding.
What was measured
Units of red cells transfused, millilitres of blood lost, and odds of re-operation for bleeding
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Desborough et al. pooled ten randomised trials with 596 participants, all in cardiac surgery, with platelet dysfunction due to antiplatelet agents in six trials and to cardiopulmonary bypass in four. Patients receiving desmopressin were transfused fewer red cells (mean difference -0.65 units, 95% CI -1.16 to -0.13), lost less blood (mean difference -253.93 mL, 95% CI -408.01 to -99.85) and had lower odds of re-operation for bleeding (Peto odds ratio 0.39, 95% CI 0.18 to 0.84). The authors state there were too few events to determine whether thrombotic risk changed, and grade the evidence very low to moderate certainty, "suggesting considerable uncertainty over the results". A separate 2023 Cochrane overview of interventions to reduce transfusion in hip fracture surgery searched specifically for desmopressin among other agents and found no systematic review of it in that setting at all.
Written into the record, not signed off as a reviewed claim
The FDA removed bedwetting from the nasal spray label in December 2007
In plain words
For years the nasal spray was a standard treatment for children who wet the bed. After repeated reports of dangerously low blood sodium and seizures, the FDA required the label to be changed and the indication went away.
What was measured
That an effective antidiuretic is a safe antidiuretic in a population that is otherwise well — the assumption the enuresis indication was built on
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Following a United States FDA request in December 2007 that the prescribing information for desmopressin nasal spray be updated, the spray is no longer indicated for primary monosymptomatic nocturnal enuresis or for use in patients at risk of hyponatraemia. Multiple reports of hyponatraemia in patients treated for nocturia, mainly elderly, drove the wider awareness. Vande Walle and colleagues, reviewing the safety question, note that hyponatraemia is reported far more often with the nasal spray than with the tablet, and attribute that partly to the spray having been the only available route in many countries for over a decade and partly to its higher and more variable bioavailability. Their own position is that the risk reflects misuse rather than an inherent property of the molecule — which is an argument about attribution, not a dispute about the events.
Written into the record, not signed off as a reviewed claim
Stimate was recalled as a superpotent drug in 2020 and never came back
In plain words
The concentrated nasal spray used specifically for bleeding disorders was pulled from the market in July 2020 because vials contained more drug than the label said. It is a Class I recall — the FDA category for a product that can cause serious harm or death — and the product is now discontinued.
What was measured
Recall classification and stated reason for recall
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
On 21 July 2020 Ferring Pharmaceuticals initiated a voluntary Class I recall of Stimate (desmopressin acetate) nasal spray 1.5 mg/mL, manufactured for CSL Behring, recall number D-1506-2020, with the stated reason "Superpotent Drug". Stimate was approved as NDA 020355 on 7 March 1994 and every product under that application is now listed as discontinued in Drugs@FDA. A superpotency failure in this particular drug is not a routine quality deviation: the entire hazard of desmopressin is dose-dependent water retention, so a vial delivering more than its label states delivers exactly the harm the boxed warning describes.
Source
openFDA drug enforcement record D-1506-2020, Class I, recall initiated 21 July 2020; Drugs@FDA NDA 020355 (STIMATE)
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
verified
Review state
Written into the record, not signed off as a reviewed claim
Four formulations approved for urinary indications are all now discontinued
In plain words
Every product built around desmopressin for night-time urination has left the United States market: the original 1978 nasal spray, the 1994 haemostatic spray, and both of the nocturia products approved in 2017 and 2018.
What was measured
Marketing status of each approved application
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Drugs@FDA lists all products under NDA 017922 (DDAVP nasal solution and spray, approved 21 February 1978) as discontinued; all products under NDA 020355 (Stimate, approved 7 March 1994) as discontinued; all products under NDA 201656 (Noctiva nasal spray for nocturia due to nocturnal polyuria, approved 3 March 2017) as discontinued; and all products under NDA 022517 (Nocdurna sublingual tablets, approved 21 June 2018) as discontinued. The injection (NDA 018938, approved 30 March 1984) and the oral tablets (NDA 019955, approved 6 September 1995) remain marketed. The pattern is not random: the formulations that survived are the ones used for hormone replacement and for bleeding, and the ones that did not are the ones aimed at a symptom in an older population where the boxed hyponatraemia warning bites hardest.
Source
openFDA Drugs@FDA marketing status for NDA 017922, NDA 020355, NDA 201656, NDA 022517, NDA 018938 and NDA 019955
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
verified
Review state
Written into the record, not signed off as a reviewed claim
It cannot work where there is nothing stored, and in one subtype it causes clots
In plain words
Desmopressin does not manufacture clotting protein, it empties a store. If the store is empty, or if the protein in it is the wrong shape, releasing it either does nothing or makes things worse.
What was measured
That a drug which raises factor VIII in mild disease will do something useful in severe disease — the extrapolation the label exists to block
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The DDAVP label limits both haemostatic indications to patients with factor VIII coagulant activity above 5%, states that the drug is not indicated for severe type I von Willebrand disease or where there is evidence of an abnormal molecular form of factor VIII antigen, and warns that use in type IIB von Willebrand disease may cause thrombosis through platelet aggregation. It is also explicitly ineffective in nephrogenic diabetes insipidus, where the receptor itself is the problem. Repeated administration produces a diminishing response as endothelial stores are depleted. Every one of these limits follows directly from the mechanism being release of a pre-existing store rather than synthesis of a protein — which is the strongest argument for teaching the mechanism rather than the indication list.
This order is fixed in code and does not count clicks or time on the page.
What is not here
3 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A redesigned vasopressin that hits the V2 receptor and leaves the blood-pressure receptor alone, raising factor VIII activity by 300 to 400 percent within two hours and concentrating the urine reliably — and the low-sodium harm that comes with the kidney half of that mechanism has now driven the original nasal spray, the haemostatic nasal spray and both nocturia products off the United States market.
Recorded evidence blocks (12)
Q2
What did Desmopressin's largest trial (1087 people) and its longest (16 years) measure?
1087 people in Desmopressin's largest registered study, 16 years in its longest registered window, measuring Cmax - Maximum Observed Concentration. ClinicalTrials.gov · 2026-09-01
24 phase4, 17 phase3, 15 na, 12 phase2, 10 na or unstated, 4 phase1, 1 early phase1; NCT00223717; 2017-01; no ageing endpoint recorded. Last human test completed 2026, NCT06771128.
Interpretation These counts include studies where Desmopressin was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase4
24
phase3
17
na
15
phase2
12
na or unstated
10
phase1
4
2 more recorded rows
early phase1
1
Last recorded human testNCT06771128
2026-01-01
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Desmopressin shown biomarker?
Interpretation Cmax - Maximum Observed Concentration — the recorded outcome words.
Show the evidence
mouse
mechanism-only
rat
mechanism-only
dog
mechanism-only
humanNCT00835211
biomarker; Cmax - Maximum Observed Concentration; 81
recorded 2026-09-01 · last checked 2026-09-04
Q4
10 of Desmopressin's trials stopped: accrual/recruitment, funding/business, other?
accrual/recruitment (5), funding/business (1) and other (4): Desmopressin's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Numbe of eligible patients has been decreased over time."; 10 of 81 registered studies
Show the evidence
Trial
NCT00592566
terminated; "Numbe of eligible patients has been decreased over time."
NCT00806468
terminated; "lack of recruitment"
NCT00885924
terminated; "to include required number of patients took too much time"
NCT01530451
terminated; "Insufficient funding"
NCT01779466
terminated; "Terminated due to lack of eligible patients"
NCT02262936
terminated; "Poor recruitment"
4 further recorded trials
NCT02636387
terminated; "Low recruitment"
NCT03089073
terminated; "Enrollment challenges"
NCT03676361
withdrawn; "Not initiated"
NCT04420585
terminated; "Study was not able to meet recruitment after 9 years of trying to enroll patients on different versions of the protocol and changing recruitment strategies."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Desmopressin used Desmopressin Acetate 0.2 mg Tablets — over how long?
5 recorded entries; human; oral; also "Desmopressin Acetate 0.2 mg Tablets", "DDAVP® 0.2 mg Tablets", "Minirin Melt 120 µg, H01BA02"
Show the evidence
human
NCT00835211
Desmopressin Acetate 0.2 mg Tablets
NCT00835211
DDAVP® 0.2 mg Tablets
NCT01435083
Minirin Melt 120 µg, H01BA02
NCT01439997
Minirin Melt 60 µg
NCT05617664
oral; desmopressin 120 mcg oral tablets
recorded 2026-09-01 · last checked 2026-09-04
Q6
Desmopressin's half-life is 3.6 hours — which schedules were studied?
3.6 hours, the half-life Desmopressin's label states. openfda-label · 52680415-52a0-61c2-e063-6294a90ae27e · 2026-08-30
bioavailability 0.16% %.
Show the evidence
half life
3.6 hours hours; Desmopressin estimated elimination half-life is 3.6 hours.
bioavailability
0.16% %; Absorption Desmopressin absolute oral bioavailability is 0.16%.
metabolism
Metabolism Desmopressin is not metabolized by human CYP450 system.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of 24 hour urine volume, adherence to intervention and bleeding events did Desmopressin's trials measure?
24 hour urine volume, adherence to intervention and bleeding events lead 19 outcome terms across Desmopressin's trials. ClinicalTrials.gov · 2026-09-01
cmax maximum observed concentration, 24 hour urine volume, nocturnal voids, wake after sleep onset, sleep efficiency and sleep follow.
Show the evidence
changes in quality of life
1
decrease in supine systolic blood pressure
1
survival
1
cmax maximum observed concentration
1
24 hour urine volume
1
nocturnal voids
1
13 more recorded rows
wake after sleep onset
1
sleep efficiency
1
sleep
1
blood loss
1
urine osmolality
1
urine volume
1
pain
1
postoperative blood loss
1
adherence to intervention
1
treatment related adverse events as assessed by ctcae v4 0
1
duration of surgery
1
rate of recruitment
1
bleeding events
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Desmopressin's 10 ongoing trials reports first?
The primary outcome measure will be defined as whether or not DDAVP-stimulated PET imaging demonstrates tumor in MRI-negative cases.; Bleeding events in 24 hours after the procedure; latest 2029-01-01
Show the evidence
Trial
NCT04569591
"DDAVP for Pituitary Adenoma"; n 22; "The primary outcome measure will be defined as whether or not DDAVP-stimulated PET imaging demonstrates tumor in MRI-negative cases."; 2028-02-26
NCT05467033
"Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin"; n 424; "Bleeding events in 24 hours after the procedure"; 2026-08-31
NCT06020495
"Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia"; n 260; "reduced occurrence of overcorrection of serum sodium concentration (SNa) in the first 48 hours after randomization"; 2026-11-30
NCT06337838
"Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial"; n 100; "Rate of recruitment"; 2027-06
NCT06622187
"Bleeding Prevention With Desmopressin for Allograft Kidney Biopsies"; n 96; "Bleeding events"; 2026-06-14
NCT06635629
"Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome"; n 140; "ACTH and cortisol responses"; 2029-01-01
4 further recorded trials
NCT07199894
"Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE"; n 120; "Percentage of improvement in number of wet nights per week"; 2026-02-01
NCT07576036
"International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia"; n 800; "Osmotic demyelination syndrome"; 2026-09-30
NCT07712328
"Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors"; n 152; "Incidence of hypernatremia within the first 24 hours postoperatively"; 2028-09-01
NCT07776977
"Bedtime Device Restriction and Desmopressin in PMNE."; n 140; "Full Response Rate"; 2027-07
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 28 trials of Desmopressin posted no result?
Posted no result
28 of 28 completed trials
Registrations
NCT00209261, NCT00902655, NCT00230594, NCT00111215, NCT00816127 and NCT01994330, and 22 more
Completion dates
oldest 2005-09; newest 2023-04-01
Show the evidence
Trial
NCT00209261
2005-09
NCT00902655
2005-12
NCT00230594
2006-02
NCT00111215
2006-09
NCT00816127
2007-05
NCT01994330
2010-02
14 further recorded trials
NCT01036841
2010-04
NCT00337766
2010-09
NCT01534117
2011-11
NCT01280188
2012-08
NCT01435083
2013-07
NCT02125188
2014-08
NCT02068560
2014-12
NCT01439997
2015-02-01
NCT01606072
2015-07
NCT02538302
2015-08
NCT02937896
2016-04
NCT02368730
2016-07
NCT00223717
2017-01
NCT01623206
2017-08
Q10
At the median, Desmopressin's trials enrolled 89 people — anything larger?
Median enrolment
89
Largest enrolment
1087
Registered trials counted
79
Q11
What do 556 spontaneous reports say about Desmopressin — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Desmopressin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 556 reaction mentions were counted: hyponatraemia 247; headache 78; epistaxis 42; flushing 38. open-targets-adr · CHEMBL1200556 · 2026-06-24
Show the evidence
hyponatraemia
247
headache
78
epistaxis
42
flushing
38
convulsion
31
confusional state
30
4 more recorded rows
blood sodium decreased
26
recalled product administered
22
seizure
22
lethargy
20
recorded 2026-06-24 · last checked 2026-09-04
Q12
Was Desmopressin studied with exercise?
exercise is named in Desmopressin's label sentences: "Herein, we report principal findings of a randomized trial of intranasal desmopressin vs a standardized, moderate-intensity aerobic exercise regimen in adolescents with mild HA." openfda-label+europepmc · 2022-09-01
1 recorded statement; exercise
Show the evidence
exercise
Herein, we report principal findings of a randomized trial of intranasal desmopressin vs a standardized, moderate-intensity aerobic exercise regimen in adolescents with mild HA.
recorded 2022-09-01 · last checked 2026-09-04
Q13
What is recorded about Desmopressin and mTOR?
": DDAVP can improve DO by decreasing c-Kit expression in Bladder ICCs and regulating PI3K/AKT/mTOR signaling pathway, but not acting through autophagy." — where Desmopressin and mTOR appear together. Europe PMC · pathway abstract search · 2023-05-18
": DDAVP can improve DO by decreasing c-Kit expression in Bladder ICCs and regulating PI3K/AKT/mTOR signaling pathway, but not acting through autophagy."
autophagy
": DDAVP can improve DO by decreasing c-Kit expression in Bladder ICCs and regulating PI3K/AKT/mTOR signaling pathway, but not acting through autophagy."
AMPK
PMID 36804411
"PXL770 induced AMPK activation and dose-dependently reduced cyst growth in principal-like Madin-Darby Canine Kidney cells stimulated with forskolin and kidney epithelial cells derived from patients with ADPKD stimulated with desmopressin."
PMID 27534994
"Here we found that short-term AMPK activation by treatment with 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR; 75 min) in kidney tissue prevented baseline AQP2 apical accumulation in principal cells, but did not prevent AQP2 apical accumulation in response to the AVP analog desmopressin (dDAVP)."
PMID 27534994
"AMPK promoted Ser-261 phosphorylation and antagonized dDAVP-dependent phosphorylation of other AQP2 COOH-terminal sites in cells."
NAD+PMID 17291221
"We developed methods for prolonged (12 h), sterile, normothermic perfusion of rat kidneys and screened compounds for renal preservation including: mitochondrial transition pore inhibitor (decylubiquinone); caspase inhibitor (Z-VAD); peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists (gemfibrozil, WY-14643); antioxidants (trolox, luteolin, quercetin); growth factors (HGF, PDGF,…"
IGF-1PMID 17291221
"We developed methods for prolonged (12 h), sterile, normothermic perfusion of rat kidneys and screened compounds for renal preservation including: mitochondrial transition pore inhibitor (decylubiquinone); caspase inhibitor (Z-VAD); peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists (gemfibrozil, WY-14643); antioxidants (trolox, luteolin, quercetin); growth factors (HGF, PDGF,…"
recorded 2023-05-18 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.